Targeting Both Viral and Host Determinants of Human Immunodeficiency Virus Entry, Using a New Lentiviral Vector Coexpressing the T20 Fusion Inhibitor and a Selective CCL5 Intrakine - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Human gene therapy methods Année : 2014

Targeting Both Viral and Host Determinants of Human Immunodeficiency Virus Entry, Using a New Lentiviral Vector Coexpressing the T20 Fusion Inhibitor and a Selective CCL5 Intrakine

Résumé

Numerous strategies targeting early and late steps of the HIV life cycle have been proposed for gene therapy. However, targeting viral and host determinants of HIV entry is the only strategy that would prevent viral DNA-mediated CD4 + cell death while diminishing the possibility for the virus to escape. To this end, we devised a bicistronic lentiviral vector expressing the membrane-bound form of the T20 fusion inhibitor, referred to as the C46 peptide, and a CCR5 superagonist, modified to sequester CCR5 away from the cell surface, referred to as the P2-CCL5 intrakine. We tested the effects of the vector on HIV infection and replication, using the human CEMR5 cell line expressing CD4 and CCR5, and primary human T cells. Transduced cells expressed the C46 peptide, detected with the 2F5 monoclonal antibody by flow cytometry. Expression of the P2-CCL5 intrakine correlates with lower levels of cell surface CCR5. Complete protection against HIV infection could be observed in cells expressing the protective transgenes. Importantly, we show that the combination of the transgenes was more potent than either transgene alone, showing the interest of expressing two entry inhibitors to inhibit HIV infection. Last, genetically modified cells possessed a selective advantage over nonmodified cells on HIV challenge in vitro, showing that modified cells were protected from HIV-induced cell death. Our results demonstrate that lentiviral vectors coexpressing the T20 fusion inhibitor and the P2-CCL5 intrakine represent promising tools for HIV gene therapy.
Fichier principal
Vignette du fichier
hgtb_2E2014_2E034.pdf (477.47 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Commentaire : Le document que vous avez soumis sur HAL contient un fichier extrait d'une revue commerciale publiée. Cette revue n'autorise pas le dépôt de fichiers éditeurs et nous ne pouvons donc pas l'accepter. En revanche s'il vous est possible de nous fournir un fichier produit par vous même tel que celui que vous avez envoyé à l'éditeur, nous serons heureux de le mettre à disposition le plus tôt possible. Nous restons à votre disposition pour tous renseignements complémentaires.
Loading...

Dates et versions

inserm-01090571 , version 1 (03-12-2014)

Identifiants

Citer

Nicolas Petit, Karim Dorgham, Béatrice Levacher, Aude Burlion, Guy Gorochov, et al.. Targeting Both Viral and Host Determinants of Human Immunodeficiency Virus Entry, Using a New Lentiviral Vector Coexpressing the T20 Fusion Inhibitor and a Selective CCL5 Intrakine. Human gene therapy methods, 2014, 25 ((4)), pp.232-40. ⟨10.1089/hgtb.2014.034⟩. ⟨inserm-01090571⟩
179 Consultations
267 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More